Plain-English translation of NCT05229614 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining pembrolizumab (an immunotherapy medication you're already taking) with a specialized form of radiation called carbon ion radiotherapy can work better for people whose cancer has stabilized. Researchers want to see if adding this focused radiation to one tumor site can help control the cancer while you continue your current immunotherapy.
Right now, when cancer stops growing on immunotherapy but doesn't shrink, doctors aren't sure what to do next. This trial is exploring whether adding targeted radiation to one lesion might give the medication a better chance to work, without overwhelming your body.
You likely qualify if…
You likely don't qualify if…
You will continue taking your pembrolizumab as you normally do. At one point during the study, you will receive carbon ion radiation therapy to one of your tumors at a specialized center in Pavia, Italy. You'll have imaging scans to plan the radiation and monitor how your cancer responds. The study involves regular check-ins with the medical team to track how you're doing and whether the combination of treatments is helping.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Germany
Italy